Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 104 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Syneos Health Clear all
Completed Phase 3 Interventional

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714713
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
69
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 66 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 7, 2026, 9:24 PM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

NCT01388933
View directory record Official record
Conditions
Crohn's Disease
Interventions
TU-100, Matching Placebo
Drug
Lead sponsor
Tsumura USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Little Rock, Arkansas • Corona, California • San Carlos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 7, 2026, 9:24 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)

NCT01689831
View directory record Official record
Conditions
Tuberculosis Infection
Interventions
To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard., Reactivity of Aplisol compared to reference standard PPD-S2.
Biological
Lead sponsor
JHP Pharmaceuticals LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT03832946
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
GB0139, Placebo
Drug
Lead sponsor
Galecto Biotech AB
Industry
Eligibility
40 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
34
States / cities
Andalusia, Alabama • Jasper, Alabama • Palm Springs, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer

NCT03093870
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Varlitinib, Capecitabine, Placebo (for Varlitinib)
Drug
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
Not listed
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Gilbert, Arizona • Detroit, Michigan • St Louis, Missouri + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Pain Associated With Fibromyalgia

NCT02187159
View directory record Official record
Conditions
Pain Associated With Fibromyalgia
Interventions
DS-5565, Pregabalin, Placebo tablet, Placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease

NCT02496884
View directory record Official record
Conditions
Fibromyalgia
Interventions
DS-5565, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Phoenix, Arizona • Colton, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD

NCT03824795
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
MGB-BP-3
Drug
Lead sponsor
MGB Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Miami, Florida • Orlando, Florida • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 7, 2026, 9:24 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Equivalence Study of Specificity of PPD

NCT01798095
View directory record Official record
Conditions
Tuberculosis Infection
Interventions
Aplisol@ PPD material, Reference Standard
Biological
Lead sponsor
JHP Pharmaceuticals LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

NCT03198728
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
SOV2012-F1, AndroGel
Drug
Lead sponsor
Marius Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

NCT02851797
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
givinostat, placebo
Drug
Lead sponsor
Italfarmaco
Industry
Eligibility
6 Years to 17 Years · Male only
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Davis, California • San Diego, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 7, 2026, 9:24 PM EDT
Terminated No phase listed Observational

UCB Cimzia Pregnancy Follow-up Study

NCT02775656
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets in Participants With Moderate to Severe Pain Following Bunionectomy

NCT02487108
View directory record Official record
Conditions
Pain
Interventions
TV-46763, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Phoenix, Arizona • Anaheim, California • Bakersfield, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men

NCT04467697
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
SOV2012-F1
Drug
Lead sponsor
Marius Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Mobile, Alabama • Aventura, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

NCT04276558
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
Udonitrectag, Vehicle
Drug · Other
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Crystal River, Florida • Gainesville, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

NCT05721573
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
ABC008
Drug
Lead sponsor
Abcuro, Inc.
Industry
Eligibility
40 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 7, 2026, 9:24 PM EDT
Terminated Phase 1 Interventional

Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

NCT05625347
View directory record Official record
Conditions
Obstructive Pulmonary Function, Restrictive Pulmonary Function
Interventions
single dose (100 mg) of ASA, single dose (162 mg) of non-enteric-coated chewable aspirin tablets
Drug
Lead sponsor
Vectura, Inc.
Industry
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
Orlando, Florida • Winter Park, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 7, 2026, 9:24 PM EDT
Terminated No phase listed Observational

The Ribavirin Pregnancy Registry

NCT00114712
View directory record Official record
Conditions
Birth Defects, Pregnancy Complications, Hepatitis C
Interventions
Not listed
Lead sponsor
Syneos Health
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 7, 2026, 9:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

NCT03416335
View directory record Official record
Conditions
Neoplasms
Interventions
DSP-0509, DSP-0509, Pembrolizumab
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Indianapolis, Indiana • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

NCT02636036
View directory record Official record
Conditions
Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
Interventions
enadenotucirev, nivolumab
Biological
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Tucson, Arizona • Duarte, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

NCT03571672
View directory record Official record
Conditions
Cardiac Disease
Interventions
DEFINITY
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Tucson, Arizona • San Diego, California • Wilmington, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

NCT02810444
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
IgG Next Generation (BT595)
Biological
Lead sponsor
Biotest
Industry
Eligibility
2 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Centennial, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 7, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes

NCT03973840
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Testosterone Undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Northbrook, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 7, 2026, 9:24 PM EDT
Completed No phase listed Observational

Grass Observational Study

NCT02075138
View directory record Official record
Conditions
Grass Allergy, Rhinoconjunctivitis
Interventions
Not listed
Lead sponsor
Circassia Limited
Industry
Eligibility
12 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Normal, Illinois • Sylvania, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 7, 2026, 9:24 PM EDT